[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.176.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
August 13, 2003

Long-term Use of Hydroxyurea for Sickle Cell Anemia—Reply

Author Affiliations
 

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2003;290(6):754. doi:10.1001/jama.290.6.754-a

In Reply: We agree with Dr Killestein and colleagues that there are several reasons why our results may differ from those of their brief trial among older patients with multiple sclerosis. These include not only study design, degree and duration of exposure to cannabinoids, and dose and contents of the cannabinoid preparations, but also route of administration and ages of the participants. Nonetheless, we believe that the most important difference is that we studied healthy participants with a history of cannabinoid use. By contrast, Killestein et al1 examined patients with longstanding multiple sclerosis, a disease related to immune dysfunction.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×